COR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cencora is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has meaningful long-term business quality, but the current setup is mixed: the technical trend is not yet constructive, news sentiment is hurt by a sharp post-earnings drop and investigation headlines, analysts have broadly kept bullish ratings but cut price targets materially, and congress trading shows more selling than buying. I would not call this a clear buy today; holding off is the better call until the trend improves.
COR closed at 269.59 with a modest gain after the prior selloff, but the chart still looks weak overall. MACD histogram is positive and expanding, which suggests short-term momentum is improving. However, RSI at 47.92 is neutral, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, which signals the broader trend is still under pressure. Price is sitting near pivot support at 265.105, with resistance at 274.736 and 280.685. The recent pattern forecast also leans weak, with downside bias over the next week and month.
["Hedge funds are buying, with reported buying activity up 2472.49% over the last quarter.", "Wells Fargo and several other major firms still keep Overweight/Outperform/Buy-style ratings despite cutting targets.", "The company reaffirmed fiscal 2026 earnings guidance and announced a new $2.0 billion share buyback program.", "MACD momentum has turned positive, hinting that the post-selloff technical damage may be stabilizing."]
["The stock dropped 17.4% after second-quarter 2026 revenue of $78.3 billion missed estimates and forced a revised growth forecast.", "Cencora is now under investigation for potential securities fraud, which is a major headline overhang.", "Multiple analysts sharply cut price targets in early May, signaling reduced near-term confidence.", "Congress trading is more negative than positive, with 4 sales versus 2 purchases and larger sale amounts.", "Bearish moving averages and weak short-term price trend suggest the stock has not yet confirmed a durable recovery."]
The latest reported quarter was fiscal second quarter 2026. Revenue came in at $78.3 billion and disappointed the market, triggering a major selloff and a revised growth outlook. Even though the company later reaffirmed full-year fiscal 2026 earnings guidance, the key read-through is that growth appears to be decelerating, which is why analysts have cut targets. The financial picture is still fundamentally large and stable, but the latest quarter was not strong enough to justify aggressive buying today.
Analyst sentiment is still mostly constructive on rating labels, with Wells Fargo, Morgan Stanley, Baird, Evercore ISI, UBS, and Citi maintaining Overweight/Outperform/Buy-type views or equivalent. However, the trend in price targets is clearly downward: Wells Fargo cut to $331 from $429, Morgan Stanley to $342 from $400, Baird to $339 from $420, Evercore to $300 from $360, and Citi to $355 from $405. This means Wall Street still likes the company structurally, but pros are becoming less optimistic on near-term upside. Net view: supportive ratings, but a clear cooling in expectations.
